FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2072635384> ?p ?o ?g. }

• W2072635384 endingPage "351" @default.
• W2072635384 startingPage "340" @default.
• W2072635384 abstract "We evaluated the safety and efficacy of the 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pitavastatin in patients with mild-to-moderate increased levels of hepatic enzymes.In this 12-week, prospective, randomized, open-label, active drug-controlled, and dose-titration study, 189 subjects with elevated low-density lipoprotein cholesterol (≥3.36 mmol/L) and alanine transaminase (ALT; ×1.25≥ and ≤×2.5 ULN; 50-100 IU/L) concentrations, but nonalcoholic and serologically negative for viral hepatitis markers at screening, were randomized to 12 weeks of treatment with pitavastatin 2-4 mg/day (PITA, n = 97) or atorvastatin 10-20 mg/day (ATOR, n = 92). Pitavastatin and atorvastatin equally reduced low-density lipoprotein cholesterol concentrations (-34.6 ± 16.0% and -38.1 ± 16.2%, respectively, P < .0001 each by analysis of variance). Seven (n = 4 PITA, n = 3 ATOR) and 10 (n = 5 PITA, n = 5 ATOR) patients experienced episodes of ALT >100 IU/L at weeks 4 and 12, respectively, with one patient in each group excluded because of severe ALT elevation >3× ULN (>120 IU/L) at week 4. The 135 patients with persistently increased ALT concentrations at screening and randomization showed significant reductions in ALT after 12 weeks of treatment with PITA (n = 68, -8.4%) or ATOR (n = 67, -8.9%; P < .05, analysis of variance). Serial nonenhanced computed tomography in 38 subjects (n = 18 PITA, n = 20 ATOR) showed that both statins reduced the severity of hepatic steatosis, especially in subjects with clear hepatic steatosis at baseline (n = 9 PITA, n = 10 ATOR). Statin treatment of another 38 subjects with spontaneous normalization of ALT at randomization had little effect on ALT levels but did not induce severe ALT elevation (>100 IU/L).Conventional doses of pitavastatin and atorvastatin effectively and safely reduce elevated hepatic enzyme concentrations." @default.
• W2072635384 created "2016-06-24" @default.
• W2072635384 creator A5003146557 @default.
• W2072635384 creator A5004044984 @default.
• W2072635384 creator A5022383639 @default.
• W2072635384 creator A5023141443 @default.
• W2072635384 creator A5034392525 @default.
• W2072635384 creator A5036863413 @default.
• W2072635384 creator A5042160045 @default.
• W2072635384 creator A5072180542 @default.
• W2072635384 creator A5075257865 @default.
• W2072635384 creator A5089355127 @default.
• W2072635384 creator A5091878274 @default.
• W2072635384 date "2012-07-01" @default.
• W2072635384 modified "2023-10-15" @default.
• W2072635384 title "Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage)" @default.
• W2072635384 cites W1503584123 @default.
• W2072635384 cites W1825742435 @default.
• W2072635384 cites W1964617195 @default.
• W2072635384 cites W1988885242 @default.
• W2072635384 cites W1993129019 @default.
• W2072635384 cites W1999363190 @default.
• W2072635384 cites W2009922326 @default.
• W2072635384 cites W2030871051 @default.
• W2072635384 cites W2049509720 @default.
• W2072635384 cites W2055230161 @default.
• W2072635384 cites W2065612971 @default.
• W2072635384 cites W2094907051 @default.
• W2072635384 cites W2104754154 @default.
• W2072635384 cites W2123512407 @default.
• W2072635384 cites W2128460332 @default.
• W2072635384 cites W2136795008 @default.
• W2072635384 cites W2142636360 @default.
• W2072635384 cites W2145050940 @default.
• W2072635384 cites W2152461696 @default.
• W2072635384 cites W2155814388 @default.
• W2072635384 cites W2163014518 @default.
• W2072635384 cites W4230870013 @default.
• W2072635384 cites W52699624 @default.
• W2072635384 cites W2166091190 @default.
• W2072635384 doi "https://doi.org/10.1016/j.jacl.2012.01.009" @default.
• W2072635384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22836071" @default.
• W2072635384 hasPublicationYear "2012" @default.
• W2072635384 type Work @default.
• W2072635384 sameAs 2072635384 @default.
• W2072635384 citedByCount "65" @default.
• W2072635384 countsByYear W20726353842012 @default.
• W2072635384 countsByYear W20726353842013 @default.
• W2072635384 countsByYear W20726353842014 @default.
• W2072635384 countsByYear W20726353842015 @default.
• W2072635384 countsByYear W20726353842016 @default.
• W2072635384 countsByYear W20726353842017 @default.
• W2072635384 countsByYear W20726353842018 @default.
• W2072635384 countsByYear W20726353842019 @default.
• W2072635384 countsByYear W20726353842020 @default.
• W2072635384 countsByYear W20726353842021 @default.
• W2072635384 countsByYear W20726353842022 @default.
• W2072635384 countsByYear W20726353842023 @default.
• W2072635384 crossrefType "journal-article" @default.
• W2072635384 hasAuthorship W2072635384A5003146557 @default.
• W2072635384 hasAuthorship W2072635384A5004044984 @default.
• W2072635384 hasAuthorship W2072635384A5022383639 @default.
• W2072635384 hasAuthorship W2072635384A5023141443 @default.
• W2072635384 hasAuthorship W2072635384A5034392525 @default.
• W2072635384 hasAuthorship W2072635384A5036863413 @default.
• W2072635384 hasAuthorship W2072635384A5042160045 @default.
• W2072635384 hasAuthorship W2072635384A5072180542 @default.
• W2072635384 hasAuthorship W2072635384A5075257865 @default.
• W2072635384 hasAuthorship W2072635384A5089355127 @default.
• W2072635384 hasAuthorship W2072635384A5091878274 @default.
• W2072635384 hasConcept C126322002 @default.
• W2072635384 hasConcept C134018914 @default.
• W2072635384 hasConcept C160160445 @default.
• W2072635384 hasConcept C181199279 @default.
• W2072635384 hasConcept C185592680 @default.
• W2072635384 hasConcept C188816634 @default.
• W2072635384 hasConcept C2776175330 @default.
• W2072635384 hasConcept C2776692505 @default.
• W2072635384 hasConcept C2776877979 @default.
• W2072635384 hasConcept C2776954865 @default.
• W2072635384 hasConcept C2777482532 @default.
• W2072635384 hasConcept C2778163477 @default.
• W2072635384 hasConcept C2778606649 @default.
• W2072635384 hasConcept C2778772119 @default.
• W2072635384 hasConcept C2779134260 @default.
• W2072635384 hasConcept C2779679107 @default.
• W2072635384 hasConcept C2780072125 @default.
• W2072635384 hasConcept C55493867 @default.
• W2072635384 hasConcept C71924100 @default.
• W2072635384 hasConcept C90924648 @default.
• W2072635384 hasConceptScore W2072635384C126322002 @default.
• W2072635384 hasConceptScore W2072635384C134018914 @default.
• W2072635384 hasConceptScore W2072635384C160160445 @default.
• W2072635384 hasConceptScore W2072635384C181199279 @default.
• W2072635384 hasConceptScore W2072635384C185592680 @default.
• W2072635384 hasConceptScore W2072635384C188816634 @default.
• W2072635384 hasConceptScore W2072635384C2776175330 @default.
• W2072635384 hasConceptScore W2072635384C2776692505 @default.

• next